Marc Vallée

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

Heather Patton, Keyur Patel, Cynthia Behling et al. · Journal of Hepatology · 2003 · 374 citations

Medicine, Internal Medicine, Pharmacotherapy +16

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease

Eric J. Topol, Donald Easton, Robert A. Harrington et al. · Circulation · 2003 · 197 citations · Full text

Medicine, Cardiology, Pharmacology +14

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

Martín E. Stryjewski, Vivian H. Chu, William O’Riordan et al. · Antimicrobial Agents and Chemotherapy · 2006 · 165 citations · Full text

Pharmacy, Infectious Diseases, Microbiology +17

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Gema Ariceta, Bradley P. Dixon, Seong Heon Kim et al. · Kidney International · 2020 · 90 citations · Full text

Medicine, Hematology, Pharmacology +15